• Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated.
Essentials
• Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated.
• We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years.
• Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism.
• Patients without cancer appear to be at a negligible risk for death.
Summary. Background: Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives: To investigate the course of iSVT in the setting of an observational multicenter study. Methods: We collected longitudinal data of 411 consecutive outpatients with acute, symptomatic, objectively diagnosed iSVT who were previously included in the cross-sectional ICARO study. Four patients followed for < 30 days and 79 with concomitant deep vein thrombosis (DVT) or pulmonary embolism (PE) were excluded from the present analysis. The primary outcome was symptomatic DVT or PE. The safety outcomes were major bleeding and all-cause death. Results: The median follow-up time was 1026 days (interquartile range 610-
Introduction
Acute superficial vein thrombosis (SVT) of the lower extremities is a frequent clinical condition that is often encountered in both hospitalized and ambulatory patients. Similarly to other vein thromboses, isolated SVT (iSVT), defined as an SVT event not associated with deep vein thrombosis (DVT) or pulmonary embolism (PE), can be caused by local triggers, such as varices or venous malformations, or systemic diseases, including cancer, but can also occur in the absence of any recognizable temporary or persisting provoking risk factor [1] . It is only in the past decade that the results from registries, epidemiologic studies and clinical trials have modified the conventional idea that iSVT is a self-limiting disease associated with a negligible risk of future DVT/PE [2] [3] [4] [5] . Indeed, unprovoked iSVT has been studied as a potential marker of occult cancer, although its predictive role must be further evaluated [6, 7] , and might be associated with an increased long-term risk of DVT/ PE and mortality [8] . However, data on such a long-term risk (beyond the first 6 weeks of treatment for acute iSVT) are scarce [4, 9] . In the ICARO study [10] , which was a large retrospective multicenter cross-sectional study, we previously aimed to identify clinical variables associated with the presence of concomitant DVT in consecutive patients presenting with symptomatic SVT of the lower limbs. In the current analysis, we report the results of the long-term follow-up of patients included in the ICARO study [10] . Our main objective is to study the incidence of and factors associated with symptomatic DVT/PE, major bleeding, and death.
Patients and methods

Setting
The patients included in the present study were diagnosed with iSVT and followed at five Italian outpatient clinics between April 1994 and October 2011. All centers are hospital-based thrombosis units or anticoagulation clinics. Patients had been referred by general practitioners or by the emergency department [10] .
Study population
We included consecutive outpatients with acute symptomatic objectively diagnosed iSVT previously included in the cross-sectional ICARO study [10] and with available follow-up of a minimum of 30 days. ICARO was a cross-sectional study aimed at identifying the factors predicting incidentally detected DVT in patients presenting with signs or symptoms of acute SVT [10] . In ICARO, 494 patients were included, and the following factors were identified as predictors of concomitant DVT at ultrasonography: cancer, limb edema, rope-like sign, age ≥ 50 years, and unprovoked events. Objective iSVT diagnosis required the performance of compression B-mode ultrasound or echo-color Doppler. Exclusion criteria of the present study included: (i) the presence of signs or symptoms of PE and/or an established diagnosis of PE, as part of the exclusion criteria of the ICARO study [10] ; (ii) the detection of concomitant DVT on compression ultrasound or echo-color Doppler (n = 79, 16.2% of the ICARO population); and (iii) a follow-up duration of < 30 days (n = 4, 0.8%). These latter patients were excluded from the present analysis because the presence of DVT was probably associated with different clinical presentations and characteristics, and would have mandated different anticoagulant treatments and durations.
Efficacy and safety outcomes
The primary efficacy outcome of the present study was symptomatic DVT/PE, defined as symptomatic proximal DVT, distal DVT, or PE. The secondary efficacy outcome was recurrent SVT. The safety outcomes were major bleeding occurring during anticoagulant treatment, classified according to the ISTH criteria [11] , and death from all causes. The classification of patients with recurrence or major bleeding was based on the information reported in the original source charts. The criteria for recurrence were homogeneously used at these five centers. Information on the cause of death was systematically collected and adjudicated locally.
Data collection, follow-up, and definitions of the variables Data collection was carried out prospectively as part of the centers' standard procedures, outside the purposes of the present study: patients were followed at each center from the time of iSVT diagnosis. The screening of patients' medical charts, inclusion of patients and data extraction were conducted retrospectively in December 2012.
For all patients, we registered the following items in a computerized database with anonymized data: demographic characteristics, the presence of risk factors for venous thromboembolism (VTE), diagnostic delay, defined as time elapsed between symptom onset and diagnosis, characteristics of the thrombotic event, type and duration of anticoagulant treatment, and follow-up data on VTE events, major bleeding, and death. Following acute iSVT, standard clinical practice at each center included regular follow-up controls not related to the conduct of the present study, and a telephone contact if patients missed the next in-hospital visit. All of the centers involved in ICARO shared the concept of regular follow-up, intended as an in-hospital visit at the time of anticoagulant discontinuation followed by annual reassessment. As part of routine clinical care, all patients were instructed on how to contact the treating physicians in if there were signs or symptoms of SVT recurrence or DVT/PE.
The saphenofemoral junction was considered to be involved when the distance between thrombus and saphenofemoral junction was < 3 cm [1] . Unprovoked SVT was defined as SVT in the absence of active cancer, recent surgery or trauma, local/systemic infections, immobilization, hormonal therapy, obesity, cardiorespiratory failure, and varicose veins. The study was approved by the local Institutional Review Boards, which, owing to the retrospective nature of the study, which did not influence either the type of anticoagulant treatment or patients' follow-up schedule, waived the need for informed consent.
Statistical methods
We expressed continuous variables as mean AE standard deviation for normally distributed data, or as median with interquartile range (IQR) when data did not have a normal distribution. Categorical data are given as counts and percentages.
We calculated the absolute risks of first symptomatic DVT/PE, SVT recurrence and major bleeding events from the time of SVT diagnosis to the end of clinical followup, which was defined as the last contact with the patient, either in-hospital, or by telephone if the patient did not show up for the scheduled visit. Additionally, we provided 3-year cumulative rates (a cut-off of 3 years was chosen, because it represents the median follow-up time of the patient population), and we calculated annual incidence rates by dividing the number of events of interest by the time to recurrence or bleeding; rates were expressed as number of events per 100 patient-years (95% confidence interval [CI] ). The Kaplan-Meier curve estimators measure the rate of patients who survived and the rate of patients who did not develop DVT/PE over the course of follow-up.
We studied the association between baseline characteristics and duration/dose of anticoagulant treatment by fitting a logistic regression model with clinically relevant variables known to influence the anticoagulant regimen: measures of association are provided as unadjusted and adjusted odds ratios (ORs). We studied the associations between anticoagulant treatment included as a time-varying variable, baseline characteristics known to influence the risk of recurrence after first VTE (male sex, active solid cancer, presence of varices, saphenofemoral junction involvement, prior DVT/PE, and family history of VTE) and future DVT/PE by the use of two multivariable Cox regression models. Model A was based on backward stepwise selection for P < 0.10 in the univariate regression analysis. Model B was adjusted for all of the covariates described: the number of the variables considered for adjustment was chosen on the basis of the number of DVT/PE events observed over follow-up for a ratio of approximately 1-10. Risk measures are provided as unadjusted and adjusted hazard ratios (HRs). A total of 12 patients without specification regarding whether or not anticoagulant treatment was prescribed were included in the regression analysis, and a total duration of '0' days of anticoagulant duration was computed. R 3.2.3 and RSTUDIO 1.0.136 (available at cran.r-project.org and at rstudio.com), and SPSS version 23.0 (IBM Corporation, Armonk, NY, USA) were used for statistical analysis.
Results
Baseline characteristics and follow-up
A total of 411 patients were included in the present analysis. The median time from iSVT diagnosis to last in-hospital visit during which control compression ultrasound was performed (n = 387) was 153 days (IQR 50-409; range 4-4827). The median time from iSVT diagnosis to last visit or last contact was 1026 days (10th percentile, 409 days; 25th percentile, 610 days; 75th percentile, 1796 days; and 90th percentile, 2915 days; range 32-6387 days), giving a total follow-up time of 556 645 patient-days, corresponding to 1525 patientyears. A total of 370 (90%) patients were diagnosed with iSVT between October 2002 and October 2011. Table 1 summarizes patients' demographics and baseline characteristics.
Anticoagulant treatment
Initial parenteral anticoagulation with heparin was used in 88.8% (n = 365) of patients, usually at a prophylactic or intermediate dosage (59.6%). The median duration of anticoagulant treatment was 30 days (IQR 28-60). Detailed characteristics of the anticoagulant regimens used are summarized in Table 2 (Table 4) . Proximal DVT or PE (associated or not associated with DVT) accounted for 71.2% (n = 43) of all events (Table 4) : an overview of the types of DVT/PE events in patient groups stratified according to the presence of risk factors is provided in Table S1 . The Kaplan-Meier curve (Fig. 1) (Table 5) .
Recurrent SVT was recorded in 100 patients with iSVT, corresponding to an absolute risk of 24.3% (95% CI 20.4-28.7%) and an annualized incidence rate of 7.9% (95% CI 6.4-9.6%). The 3-year cumulative rate for recurrent SVT was 17.5% (95% CI 14.1-21.5%) ( Table 4) . A total of 91 (91%) recurrent SVT events occurred after anticoagulant discontinuation. A total of 131 (31.9%) patients had either DVT/PE or recurrent SVT, whereas 22 (5.4%) had both.
Safety outcomes
During anticoagulant treatment, three major bleeding events occurred, giving an absolute risk of 0.7% (95% CI 0.2-2.1%) and an annualized rate of 1.4% (95% CI 0.3-4.0%) ( Table 4 ).
All-cause death was recorded in 16 (3.9% [95% CI: 2.3-6.1%]) patients, giving an annualized rate of 1.1% (95% CI 0.6-1.7%): 11.8% (95% CI 5.5-22.3%) in the presence of active cancer, and 0.5% (95% CI 0.3-1.1%) in the absence of active cancer, corresponding to absolute risks of 27.6% and 2.1%, respectively. One patient died because of fatal PE ( Table 4 ). The Kaplan-Meier curves (Fig. 2) describe the cumulative survival in the subgroups of patients with unprovoked, cancer-associated and noncancer-associated provoked iSVT. The median times to death were 250 days (IQR 80-551) in patients with cancer, and 1271 days (IQR 601-1979) in patients without cancer.
Discussion
Our cohort study contributes to providing an estimate of the risks of recurrence and death during long-term follow-up in 411 patients presenting with acute iSVT and followed for a median of ≈ 3 years. We found that the risk of future symptomatic DVT/PE in iSVT patients is not negligible (4.4% off treatment [95% CI 3.2-5.8]). Furthermore, in this population, the risk of recurrent SVT was 17.5% at 3 years, which indicates that a significant proportion of iSVT patients would probably be reexposed to temporary anticoagulation during follow-up for this reason. The risk of death was 3.9%, and half of the patients died because of active cancer.
In previous studies, the risk of DVT/PE after acute SVT was also not negligible, although rates have varied among published studies, according to the study setting, eligibility criteria, and anticoagulant treatment provided. In the CALISTO trial, which enrolled 3002 patients randomized to receive either prophylactic-dose fondaparinux or placebo during the first 45 days after acute SVT [12] , the 77-day rates of DVT/PE were 0.3% in the fondaparinux arm and 1.5% in the placebo arm. In this case, the exclusion criteria, namely cancer within the previous 6 months, recent surgery, severe chronic renal dysfunction, and a recent history of SVT or DVT/ PE, probably contributed to the selection of patients who were supposedly at lower risk of DVT/PE than those in observational cohorts including consecutively diagnosed patients. This fact may partly explain the low rates of SVT/PE observed. In contrast, in the recent SURPRISE trial, the investigators recruited symptomatic SVT patients who were expected to be at a higher risk of thromboembolic complications by fulfilling at least one of the following criteria of clinical severity: age ≥ 66 years, male sex, with prior SVT or DVT/PE, with active cancer or a history of cancer, with autoimmune disease, or with the involvement of non-varicose veins [13] . The study compared the efficacy and safety of oral rivaroxaban with those of subcutaneous fondaparinux, both given at prophylactic doses for a median of 45 days. The two groups did not differ in the primary composite efficacy outcome, including symptomatic DVT/PE, progression or recurrence of SVT, and allcause death, which occurred in 6.9% (n = 30) of the per-protocol population at 90 days (2.5% [n = 11] on treatment). The overall 90-day rate of DVT was 1.8% (n = 8), with half of the DVT events occurring after anticoagulant discontinuation. No PE and no major bleeding events were recorded [13] . In a Danish nationwide cohort study [9] , the authors reported an annualized rate of 1.8% for DVT/PE during a median follow-up time of ≈ 6 years, which indicates an 8.5-fold increased risk as compared with the general population. This risk appears to be lower than that observed in our study, and this difference may partially be explained by the designs and methodology of data collection in the two studies, as well as by the characteristics of the study populations. Furthermore, in the Danish study [9] , recruitment was extended over a 32-year period, and there is no information on the type and duration of anticoagulant treatment. More recently, the authors of the OPTIMEV study compared the outcomes in patients with a first unprovoked iSVT versus a first proximal DVT, and found that iSVT was associated with a lower risk of future DVT/PE, but with a similar risk of overall VTE events, including DVT/PE and recurrent SVT [4] . In terms of absolute numbers, the annual incidence rate of DVT/PE recurrence off anticoagulation was 2.5%, a result that is quite similar to our finding if we consider that patients with active cancer were excluded from the OPTIMEV study [4] .
In our cohort, male sex and active cancer appeared to be associated with a higher risk of recurrence (after adjustment for anticoagulant discontinuation; Table 5 ), as previously observed [14] . Conversely, no clear association was found between age or other risk factors (i.e. saphenofemoral junction involvement, or a personal history of DVT/PE) and future DVT/PE, possibly because of the relatively low number of thromboembolic events, and therefore the exploratory nature of regression model analysis. It appears that the benefit of anticoagulant treatment in terms of DVT/PE risk might not be maintained after discontinuation. In particular, an annual risk of recurrence of 4.4% after iSVT in patients off anticoagulants appears to be clinically relevant (Table 3) . Additionally, it must be noted that ≈ 50% of patients developed DVT/ PE 2 years after iSVT, indicating that the duration of anticoagulant treatment remains the main issue to be addressed, as such risk persists over time.
Patients with iSVT had an overall low risk of major bleeding, in line with what has been observed in previous SVT trials [12, 13, 15] , which reflects the dose and duration of anticoagulant treatment provided. Finally, patients with iSVT seem to have a low risk of risk of death in the absence of concomitant active cancer (Table 4 ; Fig. 1) Our study has limitations, which are mostly intrinsic to the retrospective nature of data extraction and related to the lack of fixed follow-up visits performed at each center as part of a study protocol. Therefore, one cannot exclude the possibility that our risk estimates may result in underestimation or overestimation in the case of, respectively: (i) patients with PE who had been referred to an emergency department and not directly to the outpatient clinic at the time of the event; or (ii) patients who did not develop any complication during follow-up having missed control visits and therefore been prematurely censored. Consistently, one cannot exclude the presence of performance and detection bias resulting from patients at higher risk of complications being followed more intensively at the discretion of the treating physician. Moreover, as all patients were diagnosed and followed in an out-of-hospital setting at centers specialized for the management of thrombotic disorders, they probably represent the most severe cases of iSVT (i.e. not managed directly by general practitioners). Therefore, the external validity of our results remains to be confirmed. Expectedly, as we show in Table 3 , confounding by indication is present, and probably influenced the risk estimates for recurrence, as the decision on whether and how long to anticoagulate these patients reflects normal clinical practice, and was based on individual characteristics, not on randomization. As an example, patients with prior DVT/PE received anticoagulant treatment for a median of 159 days, whereas patients without prior DVT/PE were treated for a median of 30 days. Finally, the lack of central adjudication of DVT/PE events represents an additional limitation, although one may expect uniform clinically oriented interpretation of signs and symptoms of DVT/PE across five experienced centers.
Conclusions
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